Pinnacle Wealth Planning Services Inc. Has $2.43 Million Stock Holdings in Eli Lilly and Company (NYSE:LLY)

Pinnacle Wealth Planning Services Inc. cut its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 28.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,149 shares of the company's stock after selling 1,243 shares during the period. Pinnacle Wealth Planning Services Inc.'s holdings in Eli Lilly and Company were worth $2,431,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of the business. Ethos Financial Group LLC boosted its holdings in Eli Lilly and Company by 66.5% in the fourth quarter. Ethos Financial Group LLC now owns 1,662 shares of the company's stock worth $1,285,000 after purchasing an additional 664 shares in the last quarter. Carmel Capital Partners LLC boosted its holdings in Eli Lilly and Company by 3.3% during the fourth quarter. Carmel Capital Partners LLC now owns 629 shares of the company's stock valued at $486,000 after acquiring an additional 20 shares during the period. McDonough Capital Management Inc boosted its holdings in Eli Lilly and Company by 2.5% during the fourth quarter. McDonough Capital Management Inc now owns 626 shares of the company's stock valued at $483,000 after acquiring an additional 15 shares during the period. Inceptionr LLC boosted its holdings in Eli Lilly and Company by 16.6% during the fourth quarter. Inceptionr LLC now owns 915 shares of the company's stock valued at $706,000 after acquiring an additional 130 shares during the period. Finally, Raymond James Financial Inc. bought a new stake in Eli Lilly and Company during the fourth quarter valued at about $1,240,653,000. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company Stock Performance

NYSE LLY opened at $930.12 on Thursday. The firm has a market cap of $881.91 billion, a price-to-earnings ratio of 79.43, a PEG ratio of 1.40 and a beta of 0.42. The company has a 50 day moving average of $822.55 and a 200-day moving average of $848.61. The company has a current ratio of 1.15, a quick ratio of 0.97 and a debt-to-equity ratio of 2.00. Eli Lilly and Company has a 1-year low of $711.40 and a 1-year high of $972.53.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings data on Thursday, February 6th. The company reported $5.32 earnings per share for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. On average, equities analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, March 10th. Investors of record on Friday, February 14th will be issued a $1.50 dividend. The ex-dividend date of this dividend is Friday, February 14th. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.65%. This is a positive change from Eli Lilly and Company's previous quarterly dividend of $1.30. Eli Lilly and Company's dividend payout ratio (DPR) is currently 51.24%.

Eli Lilly and Company announced that its Board of Directors has authorized a share repurchase plan on Monday, December 9th that authorizes the company to repurchase $15.00 billion in shares. This repurchase authorization authorizes the company to buy up to 2% of its shares through open market purchases. Shares repurchase plans are typically an indication that the company's board of directors believes its stock is undervalued.

Analyst Ratings Changes

LLY has been the subject of a number of recent analyst reports. Wolfe Research initiated coverage on shares of Eli Lilly and Company in a report on Friday, November 15th. They set an "outperform" rating and a $1,000.00 price target for the company. Wells Fargo & Company upped their price target on shares of Eli Lilly and Company from $970.00 to $1,100.00 and gave the company an "overweight" rating in a report on Wednesday. Bank of America restated a "buy" rating and set a $997.00 price target on shares of Eli Lilly and Company in a report on Tuesday, December 10th. Truist Financial upped their price target on shares of Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the company a "buy" rating in a report on Monday, February 3rd. Finally, Citigroup reduced their target price on shares of Eli Lilly and Company from $1,250.00 to $1,190.00 and set a "buy" rating for the company in a research note on Tuesday, January 28th. Three equities research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $1,007.50.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.